Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab versus chemotherapy after platinum failure in advanced or metastatic urothelial bladder cancer
NL-OMON45200Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Jun 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of atezolizumab in transitional cell carcinoma (TCC) (2 arms), sponsored by Roche. Primary endpoint: Overall survival. Started Jun 2015; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON45200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45200.